

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	31	Esmon charles	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:25
L17	642	endothelial protein C receptor	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2005/03/24 10:43
L20	86	Endothelial Protein C activated Receptor,	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2005/03/24 10:43
L21	72	Endothelial Cell Protein C activated Receptor,	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2005/03/24 10:13
L22	4481	activated protein C	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2005/03/24 10:15
L23	17462	protein C	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:15
L24	642	I17 or I20 or I21	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/03/24 10:16
L25	19724	I22 or I23	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/03/24 10:16
L26	341	I24 and I25	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/03/24 10:41
L27	10	I26 and I1	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/03/24 10:18
L30	1	EP "1107790"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:22
L32	1	WO "200010609"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:24

L33	0	EP "0687687"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:27
L34	4	WO "9008556"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:27
L36	5	WO "8902747"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:29
L37	1	WO "9900673"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:31
L38	2	WO "9605303"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:31
L39	2	WO "9820041"	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:32
L40	2	("5009889").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 10:32
L41	6	FUKUDOME KENJI	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:33
L42	128	I25 WITH conjugate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/03/24 10:37
L43	148	I26 and conjugate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/03/24 10:40
L45	196	I24 SAME (antibody or antibodies)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/03/24 10:42
L47	0	Endothelial Protein C activated Receptor,	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:43

L48	39	endothelial protein C receptor	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:43
L49	31	l48 and (antibody or antibodies)	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:43
L50	3	l48 SAME (antibody or antibodies)	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/03/24 10:44
L52	6	anti-EPCR antibody	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2005/03/24 10:46
L53	3	l24 and "1494" WITH mAb	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2005/03/24 10:47
L54	5	l24 and 149\$2 WITH mAb	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2005/03/24 10:47
L55	14	(US-5571786-\$ or US-5009889-\$ or US-6399064-\$ or US-5852171-\$ or US-5695993-\$ or US-6200751-\$ or US-5804392-\$ or US-6037450-\$).did. or (WO-9605303-\$ or WO-9820041-\$).did. or (WO-200010609-\$ or US-5804392-\$ or US-5695993-\$ or US-6200751-\$).did.	USPAT; EPO; DERWENT	OR	ON	2005/03/24 10:48

d his

(FILE 'HOME' ENTERED AT 17:31:15 ON 24 MAR 2005)

FILE 'MEDLINE, CANCERLIT, CAPLUS, SCISEARCH' ENTERED AT 17:31:32 ON 24 MAR 2005

L1 11 S ACTIVATED PROTEIN C (L) NUCLEUS
L2 5 DUP REM L1 (6 DUPLICATES REMOVED)
L3 428 S EPCR OR (ENDOTHELIAL PROTEIN C RECEPTOR) OR (ENDOTHELIAL ACTI
L4 79 S L3 (L) ANTIBOD?
L5 5 S L4 AND (NUCLEAR? OR NUCLEUS)
L6 3 DUP REM L5 (2 DUPLICATES REMOVED)
L7 88 S ACTIVATED PROTEIN C (L) (NUCLEAR? OR NUCLEUS)
L8 37 DUP REM L7 (51 DUPLICATES REMOVED)
L9 3 S L8 AND PY<=1998

=> d an ti so au ab pi l6 2-3

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:113075 CAPLUS

DN 138:149939

TI Marker for diagnosing breast cancer, and method for diagnosing breast cancer using the marker

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

IN Fukutome, Kenji

AB A diagnostic method is provided for evaluating the degree of breast cancer progress or the risk of breast cancer onset. A diagnostic marker substance used in the method is also provided. Endothelial protein C receptor (EPCR) is designated as the ideal marker, and an immunol. detection method using an anti-EPCR antibody is applied. The method is applicable to the detection of breast cancer cells which might be overlooked upon simply observing the form of cells or nucleus, the detection of breast cancer cells at lymph node for evaluating the degree of clearness of lymph node after the operation, and the similar evaluation and treatment after its metastasis.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003043046	A2	20030213	JP 2001-231731	20010731

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:144771 CAPLUS

DN 132:176588

TI Targeting of molecules to nuclei of cells of the large vessel endothelium using endothelial protein C receptor as a target

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

IN Esmon, Charles T.; Xu, Jun

AB Endothelial protein C receptor (

EPCR) is found primarily on endothelial cells of large vessels. EPCR translocates from the plasma membrane surface to the nucleus. Mols. which bind to EPCR can be carried from the plasma membrane surface to the nucleus. These mols. include antibodies to EPCR and activated protein C. Protein C, which also binds to EPCR, can be internalized by endothelial cells, but does not enter the nucleus. Thus, EPCR translocation from the plasma membrane to the nucleus provides a means of delivering nucleic acid such as DNA, proteins such as transcription factors, diagnostic agents or other types of drugs to the nucleus of endothelial cells, particularly those on large blood vessels. Conjugates of the materials to be delivered to the nucleus can be formed by ionic or covalent coupling. For example, proteins, including fusion proteins, can be directly conjugated to an anti-EPCR monoclonal antibody. Covalent attachment of pos. charged polymers, such as polylysine, to an anti-EPCR antibody allows nucleic acid to bind by ionic charges. Streptavidin and biotin can also be used to conjugate mols. to anti-EPCR antibodies. These conjugated antibodies are transported to the nucleus by EPCR. Examples

demonstrate selective transport to the nucleus which is mediated by EPCR. Mols. transported include activated protein C, antibodies to EPCR, and streptavidin-biotin conjugates. Modification of anti-EPCR monoclonal antibodies by covalently coupling to polylysine allows binding of an expression vector to the modified antibody and translocation to the nucleus.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010609	A1	20000302	WO 1999-US19480	19990825
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2341586	AA	20000302	CA 1999-2341586	19990825
AU 9959013	A1	20000314	AU 1999-59013	19990825
AU 765167	B2	20030911		
EP 1107790	A1	20010620	EP 1999-946649	19990825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002523381	T2	20020730	JP 2000-565929	19990825

=> d an ti so au ab 12 5

L2 ANSWER 5 OF 5 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2000:255691 SCISEARCH

TI Endothelial cell protein C receptor (EPCR) constitutively translocates into the nucleus and also mediates activated protein C, but not protein C, nuclear translocation

SO THROMBOSIS AND HAEMOSTASIS, (AUG 1999) Supp. [S], pp. 651-651.
 Publisher: F K SCHATTAUER VERLAG GMBH, P O BOX 10 45 43, LENZHALDE 3, D-70040 STUTTGART, GERMANY.
 ISSN: 0340-6245.

AU Xu J (Reprint); Esmon C T

=>

> d his

(FILE 'HOME' ENTERED AT 10:51:03 ON 24 MAR 2005)

FILE 'MEDLINE, CANCERLIT, CAPLUS, SCISEARCH' ENTERED AT 10:51:35 ON 24 MAR 2005

E ESMON CHARLES/AU

L1 2 S E3
L2 260 S E4
L3 262 S L1 OR L2
L4 428 S EPCR OR (ENDOTHELIAL PROTEIN C RECEPTOR) OR (ENDOTHELIAL ACTI
L5 119044 S ACTIVATED PROTEIN C OR (PROTEIN C)
L6 390 S L4 AND L5
L7 49 S L3 AND L6
L8 42 DUP REM L7 (7 DUPLICATES REMOVED)
L9 42 FOCUS L8 1-
L10 12 S L9 AND PY<=1998
L11 12 FOCUS L10 1-
L12 79 S L4 (L) ANTIBOD?
L13 30 DUP REM L12 (49 DUPLICATES REMOVED)
L14 3 S L13 AND PY<=1998
L15 16871 S L5 AND (CONJUGAT? OR CHIMER? OR FUSION? OR LINK? OR JOIN?)
L16 8087 S L15 AND PY<=1998
L17 8087 FOCUS L16 1-
L18 6722 S L15 AND PY<=1997
L19 6722 FOCUS L18 1-
L20 5302 S L16 AND (OLIGO? OR RIBO? OR ANTI? OR DIAGNOSTIC OR TRANSCRIPT
L21 5302 FOCUS L20 1-
L22 5302 S L16 (L) (OLIGO? OR RIBO? OR ANTI? OR DIAGNOSTIC OR TRANSCRIPT
L23 119044 S L5 AND (PROTEIN OR ANTIBOD? (L) CONJUG?)
L24 119044 S L5 (L) (PROTEIN OR ANTIBOD? (L) CONJUG?)
L25 242 S L5 (L) ((PROTEIN OR ANTIBOD?) (L) CONJUG?)
L26 186 DUP REM L25 (56 DUPLICATES REMOVED)
L27 74 S L26 AND PY<=1998
L28 62 S L26 AND PY<=1997
L29 62 FOCUS L28 1-
L30 242 S L5 (L) (PROTEIN (L) CONJUG?)
L31 109 S L30 AND PY<=1998
L32 74 DUP REM L31 (35 DUPLICATES REMOVED)
L33 74 FOCUS L32 1-
L34 15 S L33 (L) (PROTEIN (5W) CONJUG?)
L35 15 SORT L34 PY
L36 187 S (ACTIVATED PROTEIN C OR (PROTEIN C)) (5W) (CONJUGAT? OR LINK? O
L37 142 DUP REM L36 (45 DUPLICATES REMOVED)
L38 65 S L37 AND PY<=1998
L39 65 SORT L38 PY
L40 65 FOCUS L39 1-
L41 7 S (ACTIVATED PROTEIN C OR (PROTEIN C)) (5W) (BIOTIN OR STREPTAVID
L42 5 DUP REM L41 (2 DUPLICATES REMOVED)

=> d an ti so au ab pi l41 5

L41 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:144771 CAPLUS

DN 132:176588

TI Targeting of molecules to nuclei of cells of the large vessel endothelium
using endothelial protein C receptor as a target

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

IN Esmon, Charles T.; Xu, Jun

AB Endothelial protein C receptor (EPCR) is found primarily on endothelial
cells of large vessels. EPCR translocates from the plasma membrane
surface to the nucleus. Mols. which bind to EPCR can be carried from the
plasma membrane surface to the nucleus. These mols. include antibodies to
EPCR and activated protein C. Protein C, which also binds to EPCR, can be
internalized by endothelial cells, but does not enter the nucleus. Thus,
EPCR translocation from the plasma membrane to the nucleus provides a
means of delivering nucleic acid such as DNA, proteins such as
transcription factors, diagnostic agents or other types of drugs to the
nucleus of endothelial cells, particularly those on large blood vessels.

Conjugates of the materials to be delivered to the nucleus can be formed by ionic or covalent coupling. For example, proteins, including fusion proteins, can be directly conjugated to an anti-EPCR monoclonal antibody. Covalent attachment of pos. charged polymers, such as polylysine, to an anti-EPCR antibody allows nucleic acid to bind by ionic charges. Streptavidin and biotin can also be used to conjugate mols. to anti-EPCR antibodies. These conjugated antibodies are transported to the nucleus by EPCR. Examples demonstrate selective transport to the nucleus which is mediated by EPCR. Mols. transported include activated protein C, antibodies to EPCR, and streptavidin-biotin conjugates. Modification of anti-EPCR monoclonal antibodies by covalently coupling to polylysine allows binding of an expression vector to the modified antibody and translocation to the nucleus.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010609	A1	20000302	WO 1999-US19480	19990825
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2341586	AA	20000302	CA 1999-2341586	19990825
	AU 9959013	A1	20000314	AU 1999-59013	19990825
	AU 765167	B2	20030911		
	EP 1107790	A1	20010620	EP 1999-946649	19990825
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002523381	T2	20020730	JP 2000-565929	19990825